FDA Expands Use of Pembrolizumab to Two Additional Cancer Types
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab...
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab...
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah)...
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
Last week, the U.S. Food and Drug Administration (FDA) approved the antihormone agent apalutamide (Erleada) for treating men with...
The field of medical oncology is undergoing a remarkable transformation. Cancers that were once considered death sentences, such as...
The U.S. Food and Drug Administration (FDA) recently added a new therapeutic to the armamentarium for oncologists treating patients...
On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain...
A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical...